137 results
8-K
EX-99.1
TVTX
Travere Therapeutics Inc
15 Feb 24
Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
4:05pm
. Topline results from the HARMONY Study are expected in 2026.
The Company will also be initiating the ENSEMBLE Study, a Phase 3b, open-label, long-term extension … , that will evaluate the ongoing efficacy and long-term safety of pegtibatinase in participants with HCU following their completion of the Phase
8-K
EX-99.1
TVTX
Travere Therapeutics Inc
8 Jan 24
Travere Therapeutics Provides Corporate Update and 2024 Outlook
7:07am
from the HARMONY Study are expected in 2026.
The Company will also be initiating the ENSEMBLE Study, a Phase 3b, open-label, long-term extension … , that will evaluate the ongoing efficacy and long-term safety of pegtibatinase in participants with HCU following their completion of the COMPOSE Study
8-K
EX-99.1
kive atn8zrhihw
7 Nov 23
Travere Therapeutics Reports Third Quarter 2023 Financial Results
4:04pm
8-K
xl3qp5e
21 Sep 23
Other Events
7:35am
8-K/A
EX-10.1
sy4l6czlvvhyxmw5 ye
17 Aug 22
Departure of Directors or Certain Officers
5:20pm
8-K
EX-1.1
g4xwfwl
11 Mar 22
Travere Announces Proposed Convertible Senior Notes Offering
4:06pm
424B5
ht8gx
9 Mar 22
Prospectus supplement for primary offering
4:20pm
424B5
kmjk2a7 l1x33w9viw4
8 Mar 22
Prospectus supplement for primary offering
7:41am